Alnylam Grants Hayashi Kasei License to Kreutzer-Limmer Patents for the RNAi Research Products Market
News Jul 20, 2007
Alnylam Pharmaceuticals, Inc. and Hayashi Kasei have announced that Alnylam has granted Hayashi Kasei a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"This license agreement with Hayashi Kasei, one of the leading suppliers of siRNAs in Japan and Korea, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi," said Barry Greene, Chief Operating Officer of Alnylam.
"Alnylam continues to leverage its leading intellectual property estate through relationships worldwide that we expect will create value today and in the future. With approximately 30 licenses granted in the U.S., European, and Asian markets, including 14 with research product suppliers, we believe that the vast majority of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property," Greene continued.
"Obtaining a license to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the global life sciences marketplace," said Hayashi Hirotake, Managing Director of Hayashi Kasei. "This agreement with Alnylam, a leader in the field of RNAi, reinforces our ability to become a leading supplier of innovative reagent products to the pharmaceutical and research community worldwide."
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE
New Blood Test Developed to Diagnose Ovarian CancerNews
Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.READ MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018